VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

VJVirtual | Isavuconazole: primary anti-fungal prophylaxis in AML and MDS

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the use of isavuconazole, an extended spectrum mold-active triazole, investigated as a primary anti-fungal prophylaxis in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), as evaluated in an open-label, prospective, Phase II study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter